Camp4 Therapeutics Corp. Files 8-K for Material Agreement
Ticker: CAMP · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1736730
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Camp4 Therapeutics signed a big deal, filing an 8-K on Dec 18, 2025.
AI Summary
On December 18, 2025, Camp4 Therapeutics Corp. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this event. The company is incorporated in Delaware and its principal executive offices are located in Cambridge, MA.
Why It Matters
This filing indicates a significant development for Camp4 Therapeutics Corp., likely involving a new partnership, acquisition, or financing, which could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their terms, making the situation potentially volatile.
Key Numbers
- 001-42365 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1152476 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Camp4 Therapeutics Corp. (company) — Registrant
- December 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Camp4 Therapeutics Corp. on December 18, 2025?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into.
What other items are included in this 8-K filing besides the material definitive agreement?
The filing also includes financial statements and exhibits.
Where are Camp4 Therapeutics Corp.'s principal executive offices located?
Camp4 Therapeutics Corp.'s principal executive offices are located at One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139.
In which state was Camp4 Therapeutics Corp. incorporated?
Camp4 Therapeutics Corp. was incorporated in Delaware.
What is the SEC file number for Camp4 Therapeutics Corp.?
The SEC file number for Camp4 Therapeutics Corp. is 001-42365.
Filing Stats: 825 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2025-12-18 17:15:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Market
- $6.00 — ommon Stock "), at an offering price of $6.00 per Share. All of the Shares are being
- $28.0 million — from the offering will be approximately $28.0 million after deducting underwriting discounts
Filing Documents
- camp-20251218.htm (8-K) — 31KB
- exhibit11formxunderwriting.htm (EX-1.1) — 248KB
- exhibit51-opinion.htm (EX-5.1) — 9KB
- image_0a.jpg (GRAPHIC) — 36KB
- image_1a.jpg (GRAPHIC) — 10KB
- 0001628280-25-058009.txt ( ) — 535KB
- camp-20251218.xsd (EX-101.SCH) — 2KB
- camp-20251218_lab.xml (EX-101.LAB) — 24KB
- camp-20251218_pre.xml (EX-101.PRE) — 14KB
- camp-20251218_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On December 18, 2025, CAMP4 Therapeutics Corporation (the "Company"), entered into an underwriting agreement (the " Underwriting Agreement ") with Leerink Partners LLC (" Leerink Partners "), relating to an offering of 5,000,000 shares (the " Shares "), of its common stock, par value $0.0001 per share (the " Common Stock "), at an offering price of $6.00 per Share. All of the Shares are being sold by the Company. The Company estimates that the net proceeds from the offering will be approximately $28.0 million after deducting underwriting discounts and commissions and estimated offering expenses. The Shares will be issued pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (the " SEC "), on November 10, 2025 (File No. 333-291432). A prospectus supplement relating to the offering was filed with the SEC on December 18, 2025. The closing of the offering is expected to take place on or about December 19, 2025, subject to the satisfaction of customary closing conditions. The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and Leerink Partners, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. In addition, subject to certain exceptions, the Company and its executive officers and directors and certain stockholders have agreed not to offer, sell, transfer or otherwise dispose of any shares of common stock during the 60-day period following the date
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated December 18, 2025, by and between CAMP4 Therapeutics Corporation and Leerink Partners LLC 5.1 Opinion of Ropes & Gray LLP 23.1 Consent of Ropes & Gray LLP (contained in Exhibit 5.1 above) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: December 18, 2025